2nd Annual Market & Patient Access for Chronic Disease Therapies

Chronic diseases are taking a steadily increasing share of national health spending in the developed world, especially due to an ageing population and unhealthy lifestyles.

Such diseases are also rapidly gaining prevalence also in developing countries too. Such conditions and treatments do not often seem as controversial and as high on the political, healthcare system and media‘s agenda, when compared to the very expensive cancer or orphan drugs, for example. Typically, drugs for chronic diseases are priced at very reasonable levels, yet are making a large budget impact, effecting significant percentages of the entire population. The total number of patients are growing from year to year as medicines improve in efficacy and patients live longer. Health spending on long-term diseases, is indeed a long-term problem for payers, who are now looking to reprioritise budgets in a difficult economic environment and also allocate more resources to prevention, earlier diagnosis, improved managed care, disease management, reducing wastage through better patient adherence and investing in one-off surgical procedures involving medical devices. Pharmaceutical manufacturers have a great opportunity to expand into this growing market, however future success is heavily dependent on the extent of budget restrictions and other priorities of decision makers. Innovative, flexible pricing and reimbursement models are now more essential than ever in assuring market access, including value-based pricing and pay for performance schemes. Pharma marketers need to have a clearer perspective of what are the objectives and perspectives of payers, HTAs, patient groups, as well as doctor and pharmacy associations, and how to demonstrate value in order to develop a stronger understanding of how to increase market and patient access for the long-term.

Why Attend?

• Hear experiences from policy makers and industry experts regarding strategies to contain and manage chronic disease growth with an ageing population.
• Understand how disease management can improve outcomes and market-access and hear the most up to date solutions and future trends.
• Find out what is the true growth potential in major chronic therapeutic areas and their specific challenges and opportunities.
• Learn how stakeholder mapping and building a value proposition for HTA affects your market-access results.
• Discover how market leaders are implementing innovative product-value demonstration.
• Get the best and most focused picture of today's innovative, cost containment and reimbursement models and gain first hand access to information on upcoming healthcare budget reforms.
• Benchmark, network and co-operate with policy makers and key opinion leaders.

Who will benefit

Pharmaceutical manufacturers:
Vice-Presidents, Directors, Managers involved in: Pricing & Reimbursement, Market-Access, Health Outcomes, Health Economics, Payer-Relations, Government Affairs, Regulatory Affairs, Medical, Marketing, Emerging Markets, Country Heads, Brand & Product Managers.

Solution providers & consultants:
CEOs, Business Development, Senior Consultants, Regional Heads.

Your Prestigious Speaker Panel